Stephen Blakemore joined Accent in January 2022 as Vice President of Biological and Translational Sciences, bringing more than 20 years of oncology drug development experience. Prior to joining Accent, Stephen served as Vice President of Translational Sciences and Diagnostics at Bicycle Therapeutics where he led teams developing and executing predictive and pharmacodynamic clinical biomarker strategies. He started his career in drug discovery and development at GlaxoSmithKline before taking positions of increasing leadership in translational medicine at Millenium: The Takeda Oncology Company and Epizyme. Over the course of his career, Stephen has supported efforts to bring seven candidate therapies into Phase 1 clinical development, with four currently FDA approved assets, including one therapy with a companion diagnostic. He received a B.Sc. in Biochemistry from University of London and his PhD in the field of human gene expression regulation from the University of Dundee.